Chemotherapy-Induced Alopecia Treatment Device Market (2026 - 2033)

Chemotherapy-induced Alopecia Treatment Device Market Summary

The global chemotherapy-induced alopecia treatment device market size was valued at USD 88.3 billion in 2025 and is projected to grow from USD 101.2 billion in 2026 to USD 290.8 billion by 2033, at a CAGR of 16.3% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of approximately 42.0% in 2025. Chemotherapy-induced alopecia (CIA) treatment devices are used to prevent or minimize hair loss in patients undergoing chemotherapy.

Growing awareness of the psychosocial impact of chemotherapy-induced hair loss, increasing cancer incidence, and advancements in automated and portable scalp cooling systems are driving the adoption of these devices as part of comprehensive supportive oncology care. These devices, such as scalp cooling systems, reduce the amount of chemotherapy drugs that reach the hair follicles by cooling the scalp, helping to preserve hair during treatment. The market is driven by a combination of factors, including an aging, growing population and greater exposure to various risk factors, many of which are linked to socioeconomic development. Key contributors to the rising incidence of cancer include tobacco use, alcohol consumption, and obesity, while environmental factors like air pollution continue to play a significant role.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The global cancer burden is expected to grow rapidly. According to the WHO article published in February 2024, over 35 billion new cases are projected by 2050, marking a 77% increase from the estimated 20 billion cases in 2022. The increasing prevalence of chemotherapy-induced alopecia (CIA) in pediatric patients fuels market opportunity. The demand for effective CIA treatments is driven by the psychological and social impact of hair loss, which is particularly significant in children. With ongoing research and advancements in treatment options, the market for CIA treatment devices and therapies is poised for growth, addressing the critical need for effective solutions in this vulnerable population.

Technological advancements in the market focus on enhancing the efficacy and patient comfort of existing interventions. According to a study published in June 2024 in the Journal of Clinical Oncology, advancements in scalp cooling technology have shown significant potential to prevent persistent chemotherapy-induced alopecia. The randomized controlled trial found that scalp cooling substantially reduced the risk of long-term hair loss among patients undergoing chemotherapy, highlighting its effectiveness as a supportive care intervention. These developments are encouraging broader adoption of scalp cooling systems and driving innovation to improve treatment outcomes and patient quality of life.

Clinical studies have further refined LLLT devices, demonstrating their potential in CIA treatment. For instance, a randomized controlled trial involving 106 breast cancer patients used a more advanced LLLT device with 69 laser diodes (LDs), which showed improved outcomes compared with previous models.

The trial reported statistically significant increases in hair count and width over a 4-week period, as measured by a phototrichogram, with 12 sessions of LLLT intervention. These findings suggest that advancements in LLLT technology may improve hair preservation and support a better quality of life for patients undergoing chemotherapy. While the results are encouraging, additional large-scale clinical studies are needed to further establish the efficacy of LLLT and its role alongside established approaches such as scalp cooling.

Growing awareness of CIA treatment drives market growth. According to a study published in March 2025 in Oncology Nursing Forum, chemotherapy-induced alopecia significantly affects patients' psychological well-being and quality of life, highlighting the need for early education and supportive interventions. The study emphasized that oncology healthcare professionals play a crucial role in informing patients about available pharmacological and non-pharmacological approaches to manage CIA before treatment begins.

As awareness of the emotional and social impact of hair loss increases, more patients are seeking preventive and treatment options, contributing to greater adoption of CIA management therapies. In addition, oncology teams increasingly incorporate CIA management into comprehensive cancer care strategies, while collaboration between oncologists and dermatology specialists continues to improve patient support and treatment adherence throughout the cancer journey.

Analyst Perspective

The chemotherapy-induced alopecia treatment device market is becoming an increasingly important component of supportive cancer care, driven by the rising global incidence of cancer and growing awareness of chemotherapy-induced hair loss. Healthcare providers are placing greater emphasis on improving patients' quality of life during cancer treatment, which is accelerating the adoption of scalp cooling devices. In addition, technological advancements, including portable and automated scalp cooling systems that enhance patient comfort and ease of use, are expected to further drive market demand. To strengthen their market position, manufacturers are focusing on generating robust clinical evidence to validate the safety and efficacy of their devices, expanding collaborations with cancer treatment centers and research institutions, and increasing their presence in emerging geographic markets. These strategies are expected to support wider adoption and long-term market growth.

Product Insights

The manual cooling systems segment led the market with the largest revenue share of 51.5% in 2025, driven by ongoing product advancements, growing initiatives by key companies, and rising cancer prevalence. Manual cooling systems for chemotherapy-induced alopecia (CIA) are expanding due to the growing adoption of these devices by patients and their proven effectiveness. According to a study published in January 2025 in Supportive Care in Cancer, scalp cooling interventions significantly reduced chemotherapy-induced hair loss and improved patient satisfaction with treatment outcomes.

The study highlighted that patients using cold cap therapies reported better hair preservation and enhanced quality of life during chemotherapy. The growing body of clinical evidence supporting the efficacy of scalp cooling, combined with the convenience and accessibility of home-based manual cold cap systems, is driving increased adoption among cancer patients. As awareness of these benefits continues to grow, manual cooling systems are expected to witness sustained demand and broader market penetration as a non-invasive solution for managing chemotherapy-induced hair loss.

The automated cooling systems segment is expected to grow at a lucrative CAGR during the forecast period, driven by the increasing number of patients receiving chemotherapy and ongoing technological advancements in scalp cooling systems. Innovation in automated and portable cooling technologies is further supporting market expansion. For example, findings presented in an oral abstract at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago reported that a portable automated scalp cooling device was safe and effective in reducing chemotherapy-induced alopecia, highlighting continued progress toward more accessible and user-friendly scalp cooling solutions.

Leading companies such as Dignitana and Paxman continue to drive innovation in this segment. Dignitana's DigniCap Scalp Cooling System, for instance, uses a computerized cooling unit connected to a patient-worn cooling cap. By lowering scalp temperature, the system reduces blood flow and metabolic activity in hair follicles, thereby decreasing their exposure to chemotherapy agents and helping to minimize hair loss.

Sales Modality Insights

The rental sales segment led the market with the largest revenue share of 79.0% in 2025. Growing patient awareness of scalp cooling systems has increased demand for rental options. As more individuals seek to mitigate chemotherapy-induced hair loss, healthcare providers are expanding their services to include rental programs, enhancing accessibility. Advanced and affordable scalp cooling technology drives the market growth. Technological innovation is also supporting market growth.

For instance, in April 2024, a collaborative team from CI MED and the Grainger College of Engineering announced the development of CAPS Locks, an accessible scalp-cooling system designed to help prevent chemotherapy-induced alopecia by reducing hair loss during chemotherapy treatment. The initiative aims to improve the affordability and accessibility of scalp-cooling technology, potentially expanding patient access to CIA prevention solutions. Offering their device at less than half the rental price of existing systems and benefiting from Medicare coverage is poised to increase adoption rates and improve affordability for a broader patient base.

The direct sales segment is expected to grow at a lucrative CAGR during the forecast period. Manufacturers are expanding their direct sales efforts to reach patients and healthcare providers more effectively. This approach enables personalized customer support and streamlines access to treatment devices, thereby enhancing patient adoption and driving market growth. Increasing direct sales and strategic partnerships are expected to drive market growth.

Indication Insights

The breast cancer segment led the market with the largest revenue share of 65.5% in 2025. The rising incidence of breast cancer, technological advancements, and growing awareness are key factors contributing to market growth. According to the World Cancer Research Fund International article published in June 2024, breast cancer remains the leading cancer among women, with 2,296,840 new cases reported in 2022. This high incidence rate underscores the significant demand for effective solutions to manage chemotherapy-induced alopecia (CIA). The large number of breast cancer diagnoses presents a substantial market opportunity for CIA treatment devices, as addressing hair loss is a critical concern for many women undergoing chemotherapy.

The ovarian cancer segment is anticipated to grow at the fastest CAGR over the forecast period. Rising ovarian cancer cases, technological advancements, and growing awareness drive the market growth. According to the World Cancer Research Fund International article published in June 2024, ovarian cancer ranks as the 8th most common cancer among women and the 18th globally. This significant prevalence highlights a growing need for chemotherapy-induced alopecia (CIA) treatment devices. As the number of ovarian cancer diagnoses rises, so does the demand for effective solutions to manage the hair loss associated with chemotherapy, creating a robust market opportunity for CIA treatment innovations.

End-use Insights

The hospital segment led the market with the largest revenue share of 43.0% in 2025. Hospitals are integrating these CIA devices into their oncology departments to offer patients a proven way to mitigate chemotherapy-related hair loss. This expansion is driven by the growing recognition of the psychological and emotional benefits of preventing hair loss during cancer treatment, alongside the increasing availability of advanced, cost-effective cooling systems.

Hospitals invest in these technologies to enhance patient care and improve treatment experiences, further fueling market growth. For instance, in May 2024, it was estimated that nearly 10,000 people in Kentucky died from cancer annually, but UofL Health aims to cut that number in half with the help of state funding. A major advancement is established a USD 25 billion facility dedicated to rural cancer education and research at the UofL Health South Hospital in Bullitt County. This expansion will improve access to cancer care in rural areas, likely increasing demand for Chemotherapy-Induced Alopecia (CIA) treatment devices as more patients receive chemotherapy.

The cancer centers segment is anticipated to grow at a significant CAGR during the forecast period, supported by the global expansion of oncology care infrastructure and an increase in patient inflow for chemotherapy treatments. According to a 2024 report by the American Cancer Society, the rising cancer burden continues to drive demand for specialized cancer care facilities, leading to the expansion of oncology treatment centers and integrated supportive care services.

This growth is further accelerating the adoption of chemotherapy-induced alopecia (CIA) treatment devices, as cancer centers increasingly incorporate scalp cooling and other supportive interventions into standard treatment protocols to improve patient comfort and quality of life.

Regional Insights

North America dominated the global chemotherapy-induced alopecia treatment device market with the largest revenue share of approximately 42.0% in 2025. Rising cancer cases, product launches, regulatory approvals, and advanced healthcare infrastructure drive North America's demand for (CIA) treatment devices. According to an American Cancer Society article published in 2024, the U.S. is expected to record nearly 300,000 new cases of prostate cancer in 2024. The significant incidence and mortality rates of prostate cancer highlight the critical need for effective treatments, including those addressing chemotherapy-induced alopecia (CIA). This growing demand for supportive therapies, such as CIA treatment devices, is driving market expansion in North America as patients seek solutions to manage and mitigate the side effects of chemotherapy.

To learn more about this report, Download Free Sample Report

U.S. Chemotherapy-induced Alopecia Treatment Device Market Trends

The chemotherapy-induced alopecia treatment device market in the U.S. accounted for the largest market revenue share in North America in 2025. The rising incidence of cancer, growing awareness, and technological advancement drive the market growth. According to the National Cancer Institute’s SEER Cancer Statistics Review (2024), cancer incidence in the United States remains high, with over 2 billion new cases reported annually in recent years. Breast cancer continues to be one of the most frequently diagnosed cancers among women, contributing significantly to chemotherapy usage and thereby increasing the demand for chemotherapy-induced alopecia (CIA) treatment devices. The persistent heavy cancer burden, coupled with the increased number of technological solutions aimed toward advanced oncology treatment, as well as the technology that will make treatments easier, is also fueling the utilization of CIA administration technologies

Europe Chemotherapy-induced Alopecia Treatment Device Market Trends

The chemotherapy-induced alopecia treatment device market in Europe held the second-largest revenue market share in 2025. Rising cancer cases and technological advancements drive the demand for the market. For instance, projections suggest that Europe's aging population could lead to an additional 775,000 cancer cases by 2040 if advancements in cancer prevention and treatment are not achieved. This highlights the growing need for effective cancer care solutions, including chemotherapy-induced alopecia (CIA) devices, to manage side effects and improve patient quality of life as cancer incidence rises.

The Germany chemotherapy induced alopecia treatment device market accounted for the largest revenue share in Europe in 2025. Rising cancer incidence and government initiatives drive market growth. Germany presents over 500 000 cases annually, with the most prevalent cancers being breast, colorectal, prostate cancer, and lung cancer, as highlighted in the 2025 report on the OECD EU Country Cancer Profile: Germany. Chemo alopecia solutions play an important role in supporting patients, as does the development of devices designed to address chemotherapy-induced hair loss (CIA).

The chemotherapy-induced alopecia treatment device market in the UK held the second-largest market share in Europe in 2025. Rising cancer cases, longer chemotherapy waiting times, technological advancements, and growing awareness drive market growth. According to Euronews, in February 2024, the study found that UK cancer patients face longer wait times for chemotherapy than those in Norway and Australia. This underscores the need for better chemotherapy delivery in the UK, which could influence policy changes and enhance treatment practices. Reducing these delays is essential for better cancer outcomes, highlighting the importance of supportive treatments, such as chemotherapy-induced alopecia (CIA) devices, to improve patient care during chemotherapy.

The chemotherapy-induced alopecia treatment device market in France is anticipated to grow at a significant CAGR during the forecast period. Increasing demand for chemotherapy, technological advancement, and growing awareness drive the market growth. According to the International Agency for Research on Cancer (IARC) GLOBOCAN 2022 (updated estimates used in 2024–2025 reports), France records over 430,000 new cancer cases annually, with breast and prostate cancers among the most prevalent. This high cancer burden continues to drive demand for chemotherapy treatments, thereby increasing the need for CIA management solutions such as scalp cooling and related supportive devices.

Asia Pacific Chemotherapy-induced Alopecia Treatment Device Market Trends

The chemotherapy-induced alopecia treatment device market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The rising adoption of innovative therapies in Asia-Pacific oncology practices is driving demand for CIA treatment devices and driving market growth. According to a WTW report published in February 2026, the Asia Pacific records more than 9.8 billion new cancer cases annually, making cancer the leading condition by incidence in the region. The study highlighted that healthcare practices increasingly incorporate these advanced cancer treatments into their protocols, marking a significant shift towards more effective cancer care. This trend underscores the increasing demand for (CIA) treatment devices in the region, as patients undergoing these cutting-edge therapies are likely to experience hair loss as a side effect. Consequently, the need for effective solutions to manage chemotherapy-related alopecia is expected to rise in tandem with the adoption of these novel cancer treatments.

The China chemotherapy-induced alopecia treatment device market accounted for a significant share of the Asia Pacific market in 2025. China's growing cancer disease burden fuels the demand for the market. The most prevalent cancers included lung, colorectal, and breast cancers, with a significant proportion of new cases and deaths attributed to digestive system cancers. This high incidence of cancer highlights the growing need for chemotherapy-induced alopecia (CIA) treatment devices in China. As chemotherapy remains a primary treatment for these common cancers, the demand for effective solutions to manage chemotherapy-related hair loss is expected to increase significantly.

The chemotherapy-induced alopecia treatment device market in India is experiencing significant growth, driven by several key factors, including the rising incidence of cancer, expanding healthcare infrastructure, and technological advancements. According to the National Cancer Registry Program (ICMR-NCRP) estimates for 2024, India recorded approximately 15.3 lakh new cancer cases, reflecting a steady annual increase in disease burden. As the number of cancer cases continues to rise, the demand for supportive care solutions, such as Chemotherapy-Induced Alopecia (CIA) treatment devices, is expected to grow. With more patients undergoing chemotherapy, the need for effective solutions to manage hair loss is becoming increasingly important in India's cancer care landscape.

Latin America Chemotherapy-induced Alopecia Treatment Device Market Trends

The chemotherapy-induced alopecia treatment device market in Latin America is growing due to several factors. Increasing cancer incidence and strategic initiatives drive market growth. According to the NCBI article published in April 2024, the Choosing Wisely initiative in Latin America, supported by the Latin American and Caribbean Society of Medical Oncology (SLACOM), aims to reduce unnecessary oncology procedures and improve the overall quality of cancer care. Emphasizing evidence-based treatments and the appropriate use of chemotherapy, the initiative seeks to avoid harmful practices in oncology. This focus on optimizing cancer treatment is likely to increase demand for (CIA) treatment devices as more patients undergo carefully managed chemotherapy regimens across the region, with a growing emphasis on mitigating side effects like hair loss.

Middle East & Africa Chemotherapy-induced Alopecia Treatment Device Market Trends

The chemotherapy-induced alopecia treatment device market in the Middle East & Africa is expected to grow at a lucrative CAGR during the forecast period, due to the rising prevalence of cancer and the increasing adoption of advanced medical technologies in the region.

The Saudi Arabia chemotherapy-induced alopecia treatment device market is expected to grow at the fastest CAGR over the forecast period. Increasing cancer cases, rising healthcare expenditure, and strategic initiatives by the key players contribute to the market expansion. The upward trend highlights a growing need for supportive care solutions, including chemotherapy-induced alopecia (CIA) treatment devices. As more patients undergo chemotherapy, managing side effects like hair loss becomes increasingly important. The expanding cancer patient population underscores the need for effective CIA treatment solutions to enhance patient comfort and quality of life during cancer treatment in Saudi Arabia.

Key Chemotherapy-induced Alopecia Treatment Device Company Insights

The chemotherapy-induced alopecia (CIA) treatment device industry comprises several established and emerging players focusing on the development and commercialization of scalp cooling systems and cold cap technologies to minimize hair loss associated with chemotherapy. Key companies operating in this market include Dignitana, Paxman, Penguin Cold Caps, and Chemotherapy Cold Caps, Inc. These companies are focusing on strategies such as product innovation, technological advancements, geographic expansion, and partnerships with healthcare providers to strengthen their market position.

Market participants are also emphasizing the development of more efficient, patient-friendly, and accessible cooling technologies to address evolving patient preferences and improve treatment outcomes.

Key Chemotherapy-induced Alopecia Treatment Device Companies

The following key companies have been profiled for this study on the chemotherapy-induced alopecia treatment device market:

• Dignitana AB

• Paxman Coolers Ltd

• Penguin Cold Caps

• Chemotherapy Cold Caps, Inc.

• Aspen Systems, LLC's

• Cooler Heads Care, Inc.

• Arctic Cold Caps

• Stemtech Medical Devices

• Polarcoldcaps.com

Recent Developments

• In May 2024, Paxman introduced its Scalp Cooling Technology in two cities of India, within a recognized hospital chain, Health Care Global (HCG) cancer centers in Ahmedabad and Rajkot. The device received approval from the Central Drugs Standard Control Organization (CDSCO).

• In March 2024, Dignitana announced that one of the key hospitals in Italy, Antonio Perrino initiated clinical studies to gauge the effectiveness of DigniCap Delta Scalp Cooling System.

• In August 2024, Paxman received an initial order under a U.S. Department of Veterans Affairs contract to deploy its scalp cooling systems across 43 infusion clinics in the National Precision Oncology Program, marking a major expansion of its chemotherapy-induced alopecia (CIA) treatment device adoption in the U.S. healthcare system.

• In 2025, Paxman and Dignitana completed a strategic merger, combining their scalp cooling portfolios (Paxman Scalp Cooling System and DigniCap System) to accelerate innovation in next-generation automated cooling technologies for chemotherapy-induced alopecia management.

Global Chemotherapy-induced Alopecia Treatment Device Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global chemotherapy-induced alopecia treatment device market report based on product, sales modality, indication, end-use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Manual Cooling Systems
  • Automated Cooling Systems
• Sales Modality Outlook (Revenue, USD Billion, 2021 - 2033)
  • Rental Sales
  • Direct Sales
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Uterine Cancer
  • Others
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Cancer Centers
  • Outpatient Clinics
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait